Igm Blood Disorder

Neurodegenerative Disorder-Targeting Compound 1

HY-U00362 5mg
EUR 4292.4

Cyclic Laboratories manufactures the igm blood disorder reagents distributed by Genprice. The Igm Blood Disorder reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact igm antibody. Other Igm products are available in stock. Specificity: Igm Category: Blood Group: Disorder

Neurodegenerative Disorder-Targeting Compound 1

10mg Ask for price
Description: Neurodegenerative Disorder-Targeting Compound 1

Neurodegenerative Disorder-Targeting Compound 1

1g Ask for price
Description: Neurodegenerative Disorder-Targeting Compound 1

Neurodegenerative Disorder-Targeting Compound 1

1mg Ask for price
Description: Neurodegenerative Disorder-Targeting Compound 1

Neurodegenerative Disorder-Targeting Compound 1

50mg Ask for price
Description: Neurodegenerative Disorder-Targeting Compound 1

Neurodegenerative Disorder-Targeting Compound 1

5mg Ask for price
Description: Neurodegenerative Disorder-Targeting Compound 1

Neuromuscular Disorder-Targeting Compound 1

10mg Ask for price
Description: Neuromuscular Disorder-Targeting Compound 1

Neuromuscular Disorder-Targeting Compound 1

1g Ask for price
Description: Neuromuscular Disorder-Targeting Compound 1

Disorder information

Idiopathic Autism Spectrum Disorder Fibroblastic Cell Line (sc222)

T6362 5x10^5 cells / 1.0 ml
EUR 350

Idiopathic Autism Spectrum Disorder Fibroblastic Cell Line (sc229)

T6363 5x10^5 cells / 1.0 ml
EUR 350

HighQC™ Human IPSC From Fibroblast-Congenital Disorder Of Deglycosylation

ABC-SC2064 1 vial Ask for price
Description: Congenital Disorder Of Deglycosylation; CDDGN-GLYCANASE 1; NGLY1MALIGNANT HYPERTHERMIA SUSCEPTIBILITY 5; MHS5CALCIUM CHANNEL, VOLTAGE-DEPENDENT, L TYPE, ALPHA-1S SUBUNIT; CACNA1S; Subcollection: Heritable DiseasesPIGI Consented Sample; Affected: YES; Cells are only guaranteed with purchase of Gentaur Media and Gentaur Extra Cellular Matrix for appropriate cell culture, for 30 days from the date of shipment.

Erythropoietin (EPO) (Marker of Placentation Disorders)(rEPO/1367), 0.2mg/mL

BNUB3792-100 1uL
EUR 225
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Erythropoietin (EPO) (Marker of Placentation Disorders)(rEPO/1367), 0.2mg/mL

BNUB3792-500 1uL
EUR 485
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Erythropoietin (EPO) (Marker of Placentation Disorders)(EPO/3793R), 0.2mg/mL

BNUB3793-100 1uL
EUR 225
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Erythropoietin (EPO) (Marker of Placentation Disorders)(EPO/3793R), 0.2mg/mL

BNUB3793-500 1uL
EUR 485
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Erythropoietin (EPO) (Marker of Placentation Disorders)(rEPO/1367), 1mg/mL

BNUM3792-50 1uL
EUR 396
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Erythropoietin (EPO) (Marker of Placentation Disorders)(EPO/3793R), 1mg/mL

BNUM3793-50 1uL
EUR 396
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Erythropoietin (EPO) (Marker of Placentation Disorders)(rEPO/1367), CF647 conjugate, 0.1mg/mL

BNC473792-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Erythropoietin (EPO) (Marker of Placentation Disorders)(rEPO/1367), CF647 conjugate, 0.1mg/mL

BNC473792-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Erythropoietin (EPO) (Marker of Placentation Disorders)(EPO/3793R), CF647 conjugate, 0.1mg/mL

BNC473793-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Erythropoietin (EPO) (Marker of Placentation Disorders)(EPO/3793R), CF647 conjugate, 0.1mg/mL

BNC473793-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Erythropoietin (EPO) (Marker of Placentation Disorders)(rEPO/1367), CF568 conjugate, 0.1mg/mL

BNC683792-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Erythropoietin (EPO) (Marker of Placentation Disorders)(rEPO/1367), CF568 conjugate, 0.1mg/mL

BNC683792-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Erythropoietin (EPO) (Marker of Placentation Disorders)(EPO/3793R), CF568 conjugate, 0.1mg/mL

BNC683793-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Erythropoietin (EPO) (Marker of Placentation Disorders)(EPO/3793R), CF568 conjugate, 0.1mg/mL

BNC683793-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application